Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Outcomes and Clinical Characteristics of Adult Patients with Transplant Associated Thrombotic Microangiopathy: A Single Center Experience

Manuel Espinoza-Gutarra, Omer Jamy, Razan Mohty, Lauren Kelly Shea, Donna Salzman, Antonio Di Stasi, Ravi Bhatia, Zaid Al-Kadhimi, Sumithira Vasu

Blood (2024) 144 (Supplement 1): 7290.

https://doi.org/10.1182/blood-2024-206687

Published: 2024

Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta

Blood (2024) 144 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2024-205205

Published: 2024

Journal Articles

Influence of Siltuximab for CAR T-Cell Related CRS/Icans on CAR T-Cell Reconstitution, Function, and Clinical Outcomes

Antonio Di Stasi, Sean Patrick Bliven, Lauren Kelly Shea, Maureen Boms, Amber McKell, Rachael Shevin, Amitkumar N. Mehta, Mayur S. Narkhede

Blood (2024) 144 (Supplement 1): 4839.

https://doi.org/10.1182/blood-2024-207807

Published: 2024

Journal Articles

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

Katherine Parks, Kendall Diebold, Donna Salzman, Antonio Di Stasi, Manuel Espinoza-Gutarra, Ravi Bhatia, Zaid Al-Kadhimi, Omer Jamy

Blood (2023) 142 (Supplement 1): 7052.

https://doi.org/10.1182/blood-2023-184658

Published: 2023

Journal Articles

Early Results of MT-401 (Zedenoleucel) in Post-Transplant MRD + aml Patients

Blood (2022) 140 (Supplement 1): 12718–12719.

https://doi.org/10.1182/blood-2022-155602

Published: 2022

Journal Articles

Risk Factors and Outcomes of ICU Admission Following Allogeneic Hematopoietic Stem Cell Transplantation

Omer Hassan Jamy, John Dasher, Yanjun Chen, Kevin D. Battles, Donna Salzman, Antonio Di Stasi, Ravi Bhatia, Smita Bhatia

Blood (2021) 138 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2021-145234

Published: 2021

Journal Articles

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee, Mukta Arora, Zachariah Defilipp, Mohammad Issam Abu Zaid, Antonio Di Stasi, Vedran Radojcic, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Christine Quaranto, Aaron Schmitt, Yu Gu, Amandeep Salhotra, Iskra Pusic, Carrie Lynn Kitko

Blood (2021) 138 (Supplement 1): 263.

https://doi.org/10.1182/blood-2021-146050

Published: 2021

Journal Articles

A Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Older Patients Using Fludarabine and Total Body Irradiation

Omer Hassan Jamy, Sankalp Arora, Donna Salzman, Antonio Di Stasi, Kentaro Minagawa, Shin Mineishi, Ayman Saad

Blood (2021) 138 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2021-151153

Published: 2021

Journal Articles

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Mukta Arora, MD, Madan Jagasia, MBBS, MS, MMHC, Antonio Di Stasi, MD, Michael L Meyers, MD PhD, Christine Quaranto, Aaron Schmitt, Serap Sankoh, Mohammad Issam Abu Zaid, MBBS, Geoff R Hill, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Peter Ordentlich, PhD, Stephanie J. Lee, MDMPH

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141553

Published: 2020

Journal Articles

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Omer Jamy, MD, Racquel Innis-Shelton, MD, Susan Bal, MDMBBS, Ravi K. Paluri, MD, Samina Karim, Joseph H. Chewning, MD, Donna Salzman, MD, Luciano J. Costa, MD PhD, Antonio Di Stasi, MD, Lawrence S. Lamb, Jr., PhD, Shin Mineishi, Ayman Saad, MD

Blood (2019) 134 (Supplement_1): 2003.

https://doi.org/10.1182/blood-2019-129536

Published: 2019

Journal Articles

Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy

Omer Jamy, MD, Charles Bodine, MD, Rehan Sarmad, MD MBBS, Awal Chadha, MBBS, Pankit Vachhani, MD, Luciano J Costa, MD PhD, Ayman Saad, MD, Nikolaos Papadantonakis, MDPhD MSc, Harry P. Erba, MD PhD, Antonio Di Stasi, MD

Blood (2018) 132 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2018-99-114090

Published: 2018

Journal Articles

Autologous Hematopoietic Progenitor Cells Mobilization with Combination of Pegfilgrastim and Plerixafor: Efficacy and Cost Assessment

Luciano J. Costa, MD PhD, Racquel Innis-Shelton, MD, Joscelyn Bowersock, MT, Ayman Saad, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Nicole Watts, PharmD, Lawrence S. Lamb, Jr., PhD

Blood (2017) 130 (Supplement 1): 4708.

https://doi.org/10.1182/blood.V130.Suppl_1.4708.4708

Published: 2017

Journal Articles

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

Xiaoou Zhou, Gianpietro Dotti, Robert A. Krance, Caridad A. Martinez, Swati Naik, Rammurti T. Kamble, April G. Durett, Olga Dakhova, Barbara Savoldo, Antonio Di Stasi, David M. Spencer, Yu-Feng Lin, Hao Liu, Bambi J. Grilley, Adrian P. Gee, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner

Blood (2015) 125 (26): 4103–4113.

https://doi.org/10.1182/blood-2015-02-628354

Published: 2015

Includes: Supplemental data

Journal Articles

Influence of Pre-Transplant Cytomegalovirus (CMV) Serostatus on Post-Transplant Viral Reactivation after Allogeneic Stem Cell Transplantation in Patients Receiving Post-Transplant Cyclophosphamide for Gvhd Prophylaxis

Ravi K. Paluri, MD, Racquel Shelton, Melissa Gazi, Lawrence S. Lamb, PhD, Ayman Saad, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Shin Mineishi, MD

Blood (2014) 124 (21): 3864.

https://doi.org/10.1182/blood.V124.21.3864.3864

Published: 2014

Journal Articles

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Racquel Innis-Shelton, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Lawrence S. Lamb, PhD, Melissa Gazi, Lisa Williams, RN, Luciano J Costa, MD PhD, Harry Erba, Shin Mineishi, MD, Ayman Saad, MD

Blood (2014) 124 (21): 3911.

https://doi.org/10.1182/blood.V124.21.3911.3911

Published: 2014

Journal Articles

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

Xiaoou Zhou, Antonio Di Stasi, Siok-Keen Tey, Robert A. Krance, Caridad Martinez, Kathryn S. Leung, April G. Durett, Meng-Fen Wu, Hao Liu, Ann M. Leen, Barbara Savoldo, Yu-Feng Lin, Bambi J. Grilley, Adrian P. Gee, David M. Spencer, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner, Gianpietro Dotti

Blood (2014) 123 (25): 3895–3905.

https://doi.org/10.1182/blood-2014-01-551671

Published: 2014

Includes: Supplemental data

Journal Articles

Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial

Sai Ravi Pingali, MD, Milton Denai, M S, Antonio Di Stasi, MD, Partow Kebriaei, MD, Uday R Popat, MD, Amin Alousi, MD, Paolo Anderlini, MD, Simrit Parmar, MD, Chitra M. Hosing, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Sairah Ahmed, MD, Betul Oran, MD, Elizabeth J Shpall, MD, Issa Khouri, MD, Marina Konopleva, MD, PhD, Gheath Alatrash, D.O., Ph.D., Richard E Champlin, MD, Stefan O. Ciurea, MD

Blood (2013) 122 (21): 4523.

https://doi.org/10.1182/blood.V122.21.4523.4523

Published: 2013

Journal Articles

Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning

Blood (2013) 122 (21): 2167.

https://doi.org/10.1182/blood.V122.21.2167.2167

Published: 2013

Journal Articles

Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Amir Hamdi, MD, Raya Mawad, MD, Antonio Di Stasi, MD, Roland Bassett, MS, Roberto Ferro, MD, Ron Ram, MD, Gabriela Rondon, MD, Richard E Champlin, MD, Brenda M. Sandmaier, MD, Kristine C. Doney, MD, Merav Bar, MD, Partow Kebriaei, MD

Blood (2013) 122 (21): 3311.

https://doi.org/10.1182/blood.V122.21.3311.3311

Published: 2013

Journal Articles

Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant

Blood (2013) 122 (21): 2083.

https://doi.org/10.1182/blood.V122.21.2083.2083

Published: 2013

NARROW

Outcomes and Clinical Characteristics of Adult Patients with Transplant Associated Thrombotic Microangiopathy: A Single Center Experience

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Influence of Siltuximab for CAR T-Cell Related CRS/Icans on CAR T-Cell Reconstitution, Function, and Clinical Outcomes

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

Early Results of MT-401 (Zedenoleucel) in Post-Transplant MRD + aml Patients

Risk Factors and Outcomes of ICU Admission Following Allogeneic Hematopoietic Stem Cell Transplantation

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

A Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Older Patients Using Fludarabine and Total Body Irradiation

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy

Autologous Hematopoietic Progenitor Cells Mobilization with Combination of Pegfilgrastim and Plerixafor: Efficacy and Cost Assessment

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

Influence of Pre-Transplant Cytomegalovirus (CMV) Serostatus on Post-Transplant Viral Reactivation after Allogeneic Stem Cell Transplantation in Patients Receiving Post-Transplant Cyclophosphamide for Gvhd Prophylaxis

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial

Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning

Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only